Abstract:Patients with lung adenocarcinoma harboring somatic activating mutations in the epidermal growth factor receptor (EGFR) gene have benefited significantly from EGFR tyrosine kinase inhibitors (TKIs). However, a vast majority would eventually develop resistance to such TKIs, resulting in disease progression. T790M, a secondary mutation in exon 20 of the EGFR gene, has been identified as the major mechanism responsible for acquired EGFR-TKI resistance, accounting for roughly 50% of resistance. However, the association of T790M status and clinical outcome remains elusive. Here, we conducted a retrospective study examining the association between T790M status and prognosis on clinical samples obtained from 43patietns with EGFR-mutant lung adenocarcinoma and later acquired resistance to EGFR-TKIs. We performed capture-based targeted ultra-deep sequencing on either tumor biopsies or blood samples of 43 lung adenocarcinoma patients, who harbored EGFR mutations, and subsequently developed resistance to EGFR TKIs. We used BurningRock Biotech's panels, consisting of critical exons and introns, covering multiple classes of somatic mutations, including single nucleotide variation (SNVs), rearrangements, copy number variations (CNVs) and insertions and deletions (INDELs) to detect genetic alterations both qualitatively and quantitatively. We investigated the mutation spectrum after the development of resistance to EGFR-TKIs. Our analysis revealed 64% (18/28) of patients, harboring exon 19 deletions at baseline, acquired T790M at the time of progression. In contrast, only 33% (5/15) of patients, harboring exon 21 L858R substitutions at baseline, acquired T790M, indicating T790M mutation is more commonly found in patients with exon 19 deletions (p=0.052). Next, we associated T790M status with cumulative EGFR-TKI exposure time, and found patients had longer TKI exposure are more likely to acquire T790M mutation. The median TKI exposure time for patients who eventually acquired T790M was 19.20m ±1.86. In contrast, the median exposure time for patients who never acquired T790M 12.20m±1.20m (P =0.017). Furthermore, we investigated the presence of T790M mutation with progression free survival (PFS). Our data revealed that 68% (15/22) of patients with PFS≥12 months acquired T790M mutation after TKI exposure. In contrast, among patients with PFS< 12 months, only 38% of them acquired T790M mutation (p=0.048). Patients who eventually acquired T790M mutation have longer cumulative TKI exposure and are associated with longer PFS before the emergence of drug resistance. In addition, we also discovered that patients harboring exon 19 deletions are more likely to develop T790M mutation. Therefore, T790M status can be used as a potential biomarker for prognosis.

Distinct Resistant Mechanism and Genomic Evolution During TKI Treatment in Non-Small Cell Lung Cancer Patients with or Without Acquired T790M Mutation.

T790M Mutation is Associated with Better Efficacy of Treatment Beyond Progression with EGFR-TKI in Advanced NSCLC Patients.

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

The Impact of EGFR Exon 19 Deletion Subtypes on Clinical Outcomes in Non-Small Cell Lung Cancer

Non-invasive and Quantitative Analysis for EGFR T790M Mutation in the Patients with Advanced Non-Small Cell Lung Cancer Received EGFR-TKI Therapy.

Influence of Plasma T790M Mutation on Clinical Decision after 1st Generation EGFR-TKI Resistance in a Real-world Study

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR -Activating Mutation In Non- Small Cell Lung Cancer

T790M and acquired resistance of EGFR TKI: a literature review of clinical reports.

Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Distinct Co-Acquired Alterations and Genomic Evolution During TKI Treatment in Non-Small-cell Lung Cancer Patients with or Without Acquired T790M Mutation (vol 39, Pg 1846, 2020)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities

Clinical outcomes of platinum-based chemotherapy according to T790M mutation status in EGFR-positive non-small cell lung cancer patients after initial EGFR-TKI failure

Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study

Noninvasive Monitoring of Dynamics of Acquired Egfr-T790m Mutation and Discovery of Its Heterogeneity in Patients with Advanced Nsclc Treated with Egfr-Tki.

High-throughput Sequencing Reveals Distinct Genetic Features and Clinical Implications of NSCLC with De Novo and Acquired EGFR T790M Mutation.

Novel Resistance Mechanisms to First Generation EGFR Tyrosine Kinase Inhibitors: A Perspective Study in NSCLC Patients Using Targeted Next Generation Sequencing.

P3.02b-031 T790M: A Favorable Mutation?

P3.02b-098 Plasma T790M Mutation Associates with Extensive Progression in Non-small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors: Topic: EGFR RES

Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC

Plasma Egfr T790m Ctdna Status is Associated with Clinical Outcome in Advanced Nsclc Patients with Acquired Egfr-Tki Resistance